Known targets — ChEMBL curated mechanism
CHRNA10CHRNA9GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Neramexane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931548 | 0.78 | — | — | |
| SCHEMBL635941 | 0.74 | ESR1 (0.35) | — | |
| SCHEMBL339609 | 0.74 | — | — | |
| SCHEMBL20756316 | 0.74 | — | — | |
| SCHEMBL8941973 | 0.72 | CA2 (0.30) | — | |
| SCHEMBL6032874 | 0.69 | — | — | |
| Hydrazine SCHEMBL6945698 | 0.64 | — | — | |
| Hydrazine SCHEMBL5543279 | 0.64 | CA2 (0.50) | — | |
| Hydroxyamine SCHEMBL5552814 | 0.64 | — | — | |
| Methylamine SCHEMBL330884 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | claimed |
| EP-2419402-B1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-08-31 | — | — | EP | claimed |
| US-8784847-B2 | Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-07-22 | — | — | US | claimed |
| US-20120100184-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5,-CYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO.KGAA (DE) | 2012-04-26 | — | — | US | claimed |
| EP-2419402-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | Merz Pharma GmbH & Co. KGaA (DE) | 2012-02-22 | — | — | EP | claimed |
| WO-2010118889-A1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-10-21 | — | — | WO | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-2419402-B1 | SYNTHESIS OF 1-AMINO-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MESYLATE | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-20080194698-A1 | Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders | HERMANUSSEN MICHAEL | 2008-08-14 | — | — | US | disclosed |
| EP-1858501-A1 | NMDA RECEPTOR ANTAGONISTS IN THE MEDICAL INTERVENTION OF METABOLIC DISORDERS | Hermanussen, Michael (DE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1765287-A2 | IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS | Merz Pharma GmbH & Co. KGaA (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006096194-A2 | DRINKABLE IMMEDIATE RELEASE TABLET MADE WITH DIRECT COMPRESSION OF MEMANTINE OR NERAMEXANE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094674-A1 | NMDA RECEPTOR ANTAGONISTS IN THE MEDICAL INTERVENTION OF METABOLIC DISORDERS | HERMANUSSEN MICHAEL (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060198884-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | FOREST LABORATORIES, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| US-20060002999-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | FOREST LABORATORIES, INC. (US) | 2006-01-05 | — | — | US | disclosed |